BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26269169)

  • 1. [New progress in prostate cancer biomarker research].
    Qu M; Ren S; Sun Y
    Zhonghua Wai Ke Za Zhi; 2015 Apr; 53(4):317-20. PubMed ID: 26269169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA-based biomarkers for the diagnosis, prognosis, and therapeutic response monitoring of prostate cancer.
    Bae J; Yang SH; Kim A; Kim HG
    Urol Oncol; 2022 Mar; 40(3):105.e1-105.e10. PubMed ID: 34952790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized prostate-specific antigen threshold values to avoid overdiagnosis of prostate cancer and reduce unnecessary biopsy in elderly men.
    Kanao K; Komori O; Nakashima J; Ohigashi T; Kikuchi E; Miyajima A; Nakagawa K; Eguchi S; Oya M
    Jpn J Clin Oncol; 2014 Sep; 44(9):852-9. PubMed ID: 25030213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
    Hendriks RJ; van Oort IM; Schalken JA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary RNA-based biomarkers for prostate cancer detection.
    Martignano F; Rossi L; Maugeri A; Gallà V; Conteduca V; De Giorgi U; Casadio V; Schepisi G
    Clin Chim Acta; 2017 Oct; 473():96-105. PubMed ID: 28807541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
    Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
    Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current early diagnostic biomarkers of prostate cancer.
    Qu M; Ren SC; Sun YH
    Asian J Androl; 2014; 16(4):549-54. PubMed ID: 24830695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary biomarkers in prostate cancer detection and monitoring progression.
    Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
    Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology.
    Grizzle WE; Semmes OJ; Basler J; Izbicka E; Feng Z; Kagan J; Adam BL; Troyer D; Srivastava S; Thornquist M; Zhang Z; Thompson IM
    Urol Oncol; 2004; 22(4):337-43. PubMed ID: 15283893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer.
    Valentino A; Reclusa P; Sirera R; Giallombardo M; Camps C; Pauwels P; Crispi S; Rolfo C
    Clin Transl Oncol; 2017 Jun; 19(6):651-657. PubMed ID: 28054319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Novel Biomarkers in the Management of Prostate Cancer.
    Sanhueza C; Kohli M
    Curr Treat Options Oncol; 2018 Feb; 19(2):8. PubMed ID: 29423762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
    Bantis A; Grammaticos P
    Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.